Soleno Therapeutics with ticker code (SLNO) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 9 and 8 calculating the mean target price we have 8.67. With the stocks previous close at 1.95 this indicates there is a potential upside of 344.6%. There is a 50 day moving average of 1.94 and the 200 moving average now moves to 1.95. The market capitalisation for the company is $154m. You can visit the company’s website by visiting: http://soleno.life
Soleno Therapeutics, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia and changed its name to Soleno Therapeutics in May 2017. Soleno Therapeutics was incorporated in 1999 and is headquartered in Redwood City, California.
